Afinitor (everolimus) vs Augtyro (repotrectinib)

Afinitor (everolimus) and Ayvakyt (avapritinib, not Augtyro) are two different types of targeted cancer therapies. Afinitor is an mTOR inhibitor used to treat various types of cancer, including advanced renal cell carcinoma, certain breast cancers, and neuroendocrine tumors, among others, by inhibiting cell proliferation and angiogenesis. Ayvakyt, on the other hand, is a kinase inhibitor specifically designed for the treatment of gastrointestinal stromal tumors (GIST) with a mutation in the PDGFRA gene that cannot be surgically removed or that has spread to other parts of the body. When deciding which medication is right for an individual, it is crucial to consider the specific type of cancer, its genetic makeup, and the patient's overall health profile. A healthcare provider would determine the appropriateness of either Afinitor or Ayvakyt based on these factors and the evidence-based guidelines for the specific cancer diagnosis. It is important for patients to discuss with their oncologist to understand which treatment aligns with their cancer's characteristics and treatment goals.

Difference between Afinitor and Augtyro

Metric	Afinitor (everolimus)	Augtyro (repotrectinib)
Generic name	Everolimus	Repotrectinib
Indications	Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, renal angiomyolipoma with TSC, subependymal giant cell astrocytoma (SEGA) with TSC, renal cell carcinoma, and prevention of organ rejection	Advanced solid tumors with specific gene alterations (NTRK, ROS1, or ALK)
Mechanism of action	mTOR inhibitor	Tyrosine kinase inhibitor
Brand names	Afinitor, Zortress	Augtyro
Administrative route	Oral	Oral
Side effects	Mouth ulcers, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, pneumonitis	Dizziness, constipation, fatigue, edema, dyspnea, pain, cognitive effects, weight gain
Contraindications	Hypersensitivity to everolimus or other rapamycin derivatives	Hypersensitivity to repotrectinib or any component of the formulation
Drug class	Antineoplastic agent, mTOR kinase inhibitor	Antineoplastic agent, kinase inhibitor
Manufacturer	Novartis	Turning Point Therapeutics, Inc.

Efficacy

Efficacy of Afinitor (Everolimus) in Lung Cancer

Afinitor (everolimus) is primarily known for its use in certain types of advanced hormone receptor-positive, HER2-negative breast cancer, advanced renal cell carcinoma, and subependymal giant cell astrocytoma. However, its efficacy in lung cancer, particularly non-small cell lung cancer (NSCLC), has been explored in several studies. Everolimus targets the mTOR pathway, which is a key regulator of cell growth and proliferation. In NSCLC, everolimus has demonstrated antitumor activity in preclinical models and has been evaluated in clinical trials. Although some benefits have been observed, the results are not as robust as in other cancers, and everolimus is not a standard treatment for lung cancer. Its use may be considered in certain clinical trials or specific situations where other treatments have failed.

Efficacy of Augtyro (Repotrectinib) in Lung Cancer

Augtyro (repotrectinib) is a newer medication that targets specific genetic alterations in cancer cells, such as ROS1 and NTRK fusions, which can be present in some lung cancers. Repotrectinib is designed to inhibit these oncogenic drivers and has shown promise in early clinical trials for patients with NSCLC harboring these alterations. The efficacy of repotrectinib in lung cancer is particularly noteworthy in patients who have developed resistance to prior ROS1 inhibitors. In clinical studies, repotrectinib has demonstrated substantial antitumor activity, with a favorable safety profile in patients with ROS1-positive NSCLC, including those with central nervous system (CNS) metastases.

It is important to note that the use of both Afinitor and Augtyro in lung cancer is highly specific and dependent on individual patient factors, including the presence of certain molecular markers and previous treatment history. The efficacy of these drugs can vary significantly from patient to patient, and their use should be guided by a healthcare professional with expertise in oncology and personalized cancer therapy.

In summary, while Afinitor has shown some activity in lung cancer, it is not a standard treatment for this disease and is generally considered in a research context or after other therapies have failed. On the other hand, Augtyro has demonstrated encouraging results in NSCLC patients with specific genetic alterations and may represent a valuable option for targeted therapy in this subset of lung cancer patients. Ongoing clinical trials and research are essential to further define the role of these medications in the treatment of lung cancer.

Regulatory Agency Approvals

Afinitor

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Augtyro

Food and Drug Administration (FDA), USA

Access Afinitor or Augtyro today

If Afinitor or Augtyro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Afinitor

Buy Augtyro

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: